Millions more Americans are closer to getting a COVID-19 booster as influential government advisers on Thursday endorsed extra doses of all three of the nation’s vaccines and opened the possibility of choosing a different company’s brand for that next shot.
Certain people who received Pfizer vaccinations months ago already are eligible for a booster, and now advisers to the U.S. Centers for Disease Control and Prevention say specific Moderna and Johnson & Johnson recipients should qualify, too. And in a bigger change, the panel allowed the flexibility of “mixing and matching” that extra dose, regardless of which type people received first.
The Food and Drug Administration authorized such an expansion of the nation’s booster campaign on Wednesday, but the CDC, guided by its advisory panel, has the final word on who should roll up their sleeves. CDC Director Dr. Rochelle Walensky was expected to rule soon.
“We’re at a different place in the pandemic than we were earlier” when supply constraints meant people had to take whatever shot they were offered, noted CDC adviser Dr. Helen Keipp Talbot of Vanderbilt University.
She called it “priceless” to be able to choose a different kind of shot for the booster if, for example, someone might be at risk for a rare side effect from a specific vaccine.
There still are restrictions on who qualifies for a booster and when. Starting six months past their last Pfizer vaccination, people are urged to get a booster if they’re 65 or older, nursing home residents, or at least 50 and at increased risk of severe disease because of health problems. Boosters also were allowed, but not urged, for adults of any age at increased risk of infection because of health problems or their jobs or living conditions. That includes health care workers, teachers, and people in jails or homeless shelters.
The CDC panel backed the same booster qualifications for Moderna recipients. Moderna’s booster will come at half the dose of the original two shots.
As for the single-shot J&J vaccine, a COVID-19 booster is recommended for all recipients at least two months after vaccination. That’s because the J&J vaccine hasn’t proved as protective as the two-dose Moderna or Pfizer options.
The panel didn’t explicitly recommend that patients get a different brand than they started with, but it left open the option — saying only that a booster of some sort was recommended. And some of the advisers said they would prefer that J&J recipients receive a competitor’s booster, citing preliminary data from an ongoing government study that suggested a bigger boost in virus-fighting antibodies from that combination.
About two-thirds of Americans eligible for COVID-19 shots are fully vaccinated, and the government says getting first shots to the unvaccinated remains the priority. While health authorities hope boosters will shore up waning immunity against milder coronavirus infections, all the vaccines still offer strong protection against hospitalizations and death.
The CDC’s advisers wrestled with whether people who didn’t really need boosters might be getting them, especially otherwise healthy young adults whose only qualification was their job.
Dr. Sarah Long of Drexel University voiced concerns about opening those people to rare but serious side effects from another dose if they already were adequately protected.
“I have my own concerns that we appear to be recommending vaccines for people who I don’t think need it,” added Dr. Beth Bell of the University of Washington.
But she stressed that the vaccines work and that moving forward with the recommendations makes sense for the sake of being clear and allowing flexibility when it comes to boosters.
Despite the concerns of some members, the panel vote ended up being unanimous.
The vast majority of the nearly 190 million Americans who are fully vaccinated against COVID-19 have received the Pfizer or Moderna options, while J&J recipients account for about 15 million.